SCHEMBL4212934

SCHEMBL4212934

O=C(O)c1ccc(-c2ccccc2)cc1Nc1cccc(O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.52
SIRT1 Q96EB6 1/20 0.52
HCAR2 Q8TDS4 1/20 0.52
CYP3A4 P08684 1/20 0.51
TSHR P16473 1/20 0.51
ACMSD Q8TDX5 2/20 0.51
HNF4A P41235 1/20 0.51
ACLY P53396 3/20 0.51
GRIK1 P39086 2/20 0.50
AKR1C3 P42330 2/20 0.50
AKR1C2 P52895 2/20 0.50
MAPK8 P45983 2/20 0.50
PLK4 O00444 1/20 0.50
CHEK1 O14757 1/20 0.50
AURKA O14965 1/20 0.50
MAPK13 O15264 1/20 0.50
PDPK1 O15530 1/20 0.50
DAPK3 O43293 1/20 0.50
DYRK3 O43781 1/20 0.50
JAK2 O60674 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4222898 0.96 AKR1C3 (0.51) SIRT2SIRT1HCAR2CYP3A4TSHR
SCHEMBL4228017 0.93 AKR1C3 (0.54) SIRT2SIRT1HCAR2CYP3A4TSHR
SCHEMBL4223666 0.91 SIRT2 (0.61) SIRT2SIRT1ACMSDHNF4AACLY
SCHEMBL4209169 0.89 GRIK1 (0.58) HCAR2ACLYGRIK1AKR1C3AKR1C2
SCHEMBL4223119 0.88 AKR1C3 (0.60) SIRT2SIRT1ACMSDHNF4AACLY
SCHEMBL4221820 0.85 HNF4A (0.54) ACMSDHNF4AACLYGRIK1AKR1C3
SCHEMBL4222990 0.85 ACLY (0.59) ACMSDHNF4AACLYGRIK1AKR1C3
SCHEMBL4225722 0.84 AKR1C3 (0.64) SIRT2SIRT1HCAR2ACLYGRIK1
SCHEMBL4222620 0.84 AKR1C3 (0.66) SIRT2SIRT1HCAR2ACLYAKR1C3
SCHEMBL9719838 0.83 FABP4 (0.67) SIRT2SIRT1CYP3A4TSHRAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 SIRT2 2167/4885SIRT1 1571/4885HCAR2 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.